DOB (4-bromo-2,5-dimethoxyamphetamine; full name 2,5-dimethoxy-4-bromoamphetamine) is a synthetic psychedelic hallucinogen belonging to the DOx series of substituted amphetamines. First synthesized and characterized by Alexander Shulgin, DOB is among the most potent classical psychedelics in the amphetamine class — active at doses of 1–3 mg — and among the longest-acting, producing experiences of 16–30 hours or more. The duration and potency profile place it at the far extreme of the psychedelic amphetamine series and demand exceptional caution.
DOB's primary use context is as a research tool for studying the 5-HT2 receptor subfamily, where its high selectivity for 5-HT2B makes it pharmacologically distinct from most other psychedelics. In recreational use, its extreme potency creates substantial dosing hazard — active doses are in the microgram-to-low-milligram range, overlapping with the dose range where blotter papers or pressed tablets may be confused with LSD. Multiple poisoning incidents have occurred when DOB-adulterated LSD was unknowingly consumed at doses calibrated for LSD activity.
Safety at a Glance
High Risk- Ehrlich Test for LSD Verification
- Threshold: 0.5–1 mg | Common: 1–2 mg | Strong: 2–3 mg
- Toxicity: Extreme Duration as a Toxicological Factor The 16–30 hour duration dramatically amplifies every risk dimension. Cardi...
- Overdose risk: Overdose Internationally, DOB is a Schedule I drug under the Convention on Psychotropic Substance...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 14 hrs – 24 hrsHow It Feels
The first indication that DOB has taken hold arrives slowly, almost teasingly. An hour passes after ingestion, then two, and the only clues are a subtle electrical hum in the muscles and a faint metallic taste at the back of the throat. By the third hour, a creeping stimulation has settled into the body, unmistakable and insistent. The heart beats harder and faster than usual. The jaw tightens with a determined clench. There is a building pressure behind the eyes, as if the brain itself were swelling to accommodate something vast. The amphetamine backbone of DOB makes itself known through a driven, restless energy that anchors the entire experience in the body.
As the come-up continues to unfurl, the visual field begins to transform. Colors intensify with an almost aggressive vividness, as though someone has turned the saturation dial far past its natural limit. Geometric patterns emerge not as gentle overlays but as commanding, angular structures. They tile across surfaces with a mechanical precision, intricate and relentless, pulsing in time with the user's heartbeat. There is a sharpness to DOB's visuals that distinguishes them from softer psychedelics. Everything feels etched, heightened, almost too real. Walls, ceilings, and floors may appear to ripple with crystalline grids of impossible intricacy.
At the peak, which can stretch across four to six hours beginning around hour three or four, the stimulation and psychedelia fuse into an experience of sustained intensity. The mind races with ideas that feel both lucid and grandiose. Conversations may take on an exhausting momentum, careening through topics with manic energy. Emotionally, there is a volatility that mirrors the physical drive: euphoria, awe, irritability, and paranoia can all surface within the same hour. Body temperature regulation becomes unreliable, and fluctuations between sweating and chills are common. The pupils are widely dilated, and peripheral vasoconstriction may cause the fingers and toes to feel cold or tingling, even as the core runs hot.
The descent from DOB is one of its most defining and, for many, most punishing features. The experience does not simply end after six or eight hours. Instead, it tapers with agonizing slowness across another six to twelve hours, sometimes longer. The stimulation persists long after the psychedelic intensity has faded, leaving a wired, hollowed-out restlessness that resists sleep. The jaw remains sore. The body feels like a machine that has been running at redline for too long. When sleep finally comes, it arrives heavy and dreamless, and the following day is often marked by a dull, depleted fatigue that lingers into the evening.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(22)
- Abnormal heartbeat— Abnormal heartbeat (arrhythmia) is any deviation from the heart's normal rhythm — including beats th...
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Bodily control enhancement— Bodily control enhancement is the subjective feeling of improved physical precision, coordination, a...
- Changes in felt bodily form— Changes in felt bodily form is the experience of one's body feeling as though it has altered its phy...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Diarrhea— Diarrhea is the occurrence of frequent, loose, or watery bowel movements as a side effect of certain...
- Difficulty urinating— Difficulty urinating, also known as urinary retention, is the experience of being unable to easily p...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Increased salivation— Increased salivation (hypersalivation or sialorrhea) is the excessive production of saliva beyond wh...
- Muscle cramp— Muscle cramps are sudden, involuntary, and often painful contractions of muscles that occur as a sid...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Restless legs— Restless legs is an uncomfortable neurological effect characterized by an irresistible compulsion to...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Stamina enhancement— Stamina enhancement is an increase in one's ability to sustain physical and mental exertion over ext...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Stomach cramp— Stomach cramps are sharp, intermittent pains in the abdominal region that can occur when psychoactiv...
- Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
- Temperature regulation disruption— Impaired thermoregulation causing unpredictable fluctuations between feeling hot and cold, with risk...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Tactile(1)
- Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...
Cognitive & Perceptual Effects
Visual(19)
- After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
- Brightness alteration— Perceived increase or decrease in environmental brightness beyond actual illumination levels, common...
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
- Depth perception distortions— Alterations in how the distance of objects within the visual field is perceived, causing layers of s...
- Diffraction— The experience of seeing rainbow-like spectrums of color and prismatic halos embedded within bright ...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- External hallucination— A visual hallucination that manifests within the external environment as though it were physically r...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
- Perspective distortions— Distortion of perceived depth, distance, and size of real objects, making things appear closer, furt...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Shadow people— The perception of dark, humanoid silhouettes lurking in peripheral vision or standing in direct line...
- Symmetrical texture repetition— Textures appear to mirror and tessellate across surfaces in intricate, self-similar symmetrical patt...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Cognitive(21)
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Analysis suppression— Analysis suppression is a cognitive impairment in which the capacity for logical reasoning, critical...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Increased sense of humor— A general amplification of one's sensitivity to finding things humorous and amusing, often causing p...
- Irritability— Irritability is a sustained state of emotional reactivity in which the threshold for annoyance, frus...
- Language suppression— A diminished ability to formulate, comprehend, or articulate language, ranging from difficulty findi...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Sensed presence— Sensed presence is the vivid and often unshakeable feeling that an unseen conscious being — whether ...
- Suggestibility enhancement— Heightened receptivity to external suggestions, ideas, and influence, commonly experienced during ps...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought connectivity— A state in which disparate thoughts, concepts, and ideas become fluidly and spontaneously interconne...
- Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Auditory(1)
- Auditory hallucination— Auditory hallucination is the perception of sounds that have no external source — hearing music, voi...
Multi-sensory(2)
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
- Synaesthesia— Stimulation of one sense triggers involuntary experiences in another — seeing sounds as colors, tast...
Transpersonal(3)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Existential self-realization— A sudden, visceral realization of the profound significance and improbability of one's own existence...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
Mechanism of Action
DOB produces its psychedelic effects through 5-HT2A receptor partial agonism in the prefrontal cortex and associated regions — the universal mechanism of classical psychedelics. Its 5-HT2A binding affinity is high, contributing to potent effects at sub-milligram doses.
DOB shows remarkable selectivity for the 5-HT2B receptor subtype relative to most other psychedelics, which has made it a standard pharmacological tool for studying 5-HT2B function. This high 5-HT2B activity carries the same cardiac valvulopathy concern as chronic use of other potent 5-HT2B agonists (including ergot derivatives and appetite suppressants).
Prodrug Possibility
There is evidence suggesting DOB may function partly as a prodrug — with metabolic activation in vivo contributing to its pharmacological effects, including the extended duration. This metabolic profile complicates dose-response prediction relative to compounds with more straightforward pharmacokinetics.
Pharmacokinetics
DOB is orally active at approximately 1–3 mg. Onset is unusually slow — 2–4 hours — which creates severe redosing risk if users conclude the dose was insufficient before effects have fully developed. Peak effects are reached at 6–9 hours. Total duration is 16–30 hours, occasionally extending beyond 30 hours at higher doses. The extremely long duration and slow onset are the primary safety concerns beyond potency.
Stimulant Component
Like all DOx compounds, DOB has a pronounced amphetamine-like stimulant component alongside its psychedelic effects — elevated heart rate, blood pressure, appetite suppression, and jaw tension. This stimulant burden persists for the full duration of the experience.
Detection Methods
Urine Detection
DOB (4-bromo-2,5-dimethoxyamphetamine) is an amphetamine-derived psychedelic with a long duration of action and corresponding extended detection window. Due to its structural relationship to amphetamine, DOB and its metabolites may trigger presumptive positive results on standard amphetamine immunoassays. Urine detection windows are estimated at 2 to 4 days following ingestion when analyzed by immunoassay, and potentially longer with LC-MS/MS methods. The extended duration of action (up to 20 hours or more) means the body is eliminating parent compound and metabolites over a prolonged period.
Blood and Serum Detection
Blood detection windows for DOB are approximately 12 to 36 hours after oral ingestion, reflecting the compound's long pharmacological half-life. Peak plasma concentrations occur 2 to 4 hours post-ingestion. The slow offset of effects correlates with sustained measurable blood concentrations. LC-MS/MS provides the most sensitive and specific blood analysis.
Standard Drug Panel Inclusion
DOB is NOT specifically listed on standard 5-panel, 10-panel, or 12-panel drug screens. However, unlike most psychedelics, DOx-series amphetamines may cross-react with amphetamine immunoassays due to their intact amphetamine backbone. A presumptive positive for amphetamine on initial screening is a realistic possibility. On confirmatory testing by GC-MS or LC-MS/MS, the result would not confirm as amphetamine or methamphetamine, and would be reported as negative unless the laboratory specifically includes DOx compounds in their confirmatory panel. Most routine clinical laboratories do not test for DOx amphetamines.
Confirmatory Methods
Definitive identification of DOB requires GC-MS or LC-MS/MS with reference standards specific to DOx compounds. The amphetamine backbone makes GC-MS analysis straightforward without derivatization in most cases. Some forensic toxicology laboratories include DOx amphetamines in extended novel psychoactive substance panels. The relatively long detection window compared to other psychedelics provides a larger sampling window for confirmatory testing.
Reagent Testing (Harm Reduction)
The Marquis reagent produces variable color reactions with DOx amphetamines, ranging from orange-brown to olive-green depending on the specific compound. The Mecke reagent may produce blue-green to brown reactions. The Mandelin reagent typically shows green to brown. Critically, the Ehrlich reagent shows NO reaction with DOx amphetamines, which distinguishes them from lysergamides and tryptamines. Because DOx compounds are sometimes sold on blotter paper mimicking LSD, the Ehrlich test is an essential safety tool: absence of a purple reaction on blotter strongly suggests the substance is not LSD and may be a DOx compound or NBOMe. Given the very long duration of DOx compounds (12-24+ hours), correct identification prior to ingestion is important for safety planning.
Interactions
| Substance | Status | Note |
|---|---|---|
| 3-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 4-MMC | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 8-Chlorotheophylline | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Adrafinil | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Anandamide | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| Cannabis | Uncertain | — |
| 1,3-Butanediol | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 25E-NBOH | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T-2 | Low Risk & Synergy | Cross-tolerance exists; effects compound |
History
Synthesis and Shulgin's Characterization
DOB (2,5-dimethoxy-4-bromoamphetamine) was first synthesized and characterized by Alexander Shulgin in 1967 as part of his systematic exploration of halogenated 2,5-dimethoxyamphetamine derivatives . Having already discovered the extraordinary potency of DOM (the 4-methyl analog), Shulgin investigated how replacing the methyl group with halogens — bromine (DOB), iodine (DOI), and chlorine (DOC) — would affect pharmacological activity. DOB emerged as one of the most potent members of the DOx series, active at doses of 1 to 3 mg with effects lasting 18 to 30 hours .
Shulgin documented DOB as entry #62 in PiHKAL: A Chemical Love Story (1991), describing it as a powerful psychedelic with vivid visual effects and significant body stimulation. The compound's extreme duration and potency made it one of the earliest DOx compounds to attract serious pharmacological investigation, and it served alongside DOI as a reference agonist in structure-activity relationship studies of the serotonin 5-HT2A receptor .
Research Significance
DOB played an important role in establishing the halogenated DOx compounds as critical tools in receptor pharmacology. Along with DOI, it helped researchers map the relationship between 4-position substituents, receptor binding affinity, and psychedelic potency. Structure-activity studies using DOB and its analogs demonstrated that halogen substitution at the 4-position produced compounds more potent than their alkyl-substituted counterparts, with the order of potency for halogenated DOx analogs established as DOB > DOI approximately equal to DOC > DOF .
Scheduling
DOB was placed in Schedule I of the Controlled Substances Act in the United States and is internationally controlled under Schedule I of the United Nations Convention on Psychotropic Substances . Its scheduling reflected both its high psychedelic potency and the broader regulatory response to substituted amphetamines in the post-DOM/STP era.
References
- Shulgin, A.T. & Shulgin, A. PiHKAL: A Chemical Love Story. Transform Press, 1991. Entry #62.
- Erowid DOB Vault. Chemical and pharmacological reference.
- Frontiers in Pharmacology. "Binding and functional SAR of 4-substituted 2,5-dimethoxyphenyl isopropylamine analogues." 2023.
Harm Reduction
Ehrlich Test for LSD Verification
If using blotter papers suspected to be LSD, always use an Ehrlich reagent test. Genuine LSD produces a purple/violet color. No color change indicates absence of an indole compound — possible DOB, DOx, or NBOMe contamination. Mecke reagent (blue-green for DOB) and Hofmann reagent can help identify DOx compounds.
Dose Guidelines
- Threshold: 0.5–1 mg |Common: 1–2 mg |Strong: 2–3 mg
- These doses must be measured on a milligram-accurate scale — volumetric dosing in solution is the only safe method at this scale
- Wait a minimum of 4 hours after oral ingestion before any dose adjustment. The slow onset has caused many overdoses.
Duration Planning
Allocate 30–36 hours. Inform a trusted person of your plans. Do not take DOB if you have any obligations within 36 hours. A trip sitter committed to the full duration (or available on call) is essential.
Emergency Preparedness
Peripheral vasoconstriction symptoms (cold, pale, painful extremities) require immediate medical attention. Be transparent with emergency personnel about what was taken — medical providers can treat vasoconstriction effectively with vasodilators if they know the cause.
Avoiding Confusion with LSD
DOB has historically appeared on blotter markets as LSD. Always test before consuming — this single intervention prevents the most serious documented DOB harms.
Toxicity & Safety
Extreme Duration as a Toxicological Factor
The 16–30 hour duration dramatically amplifies every risk dimension. Cardiovascular stress from amphetamine-like stimulation persists for an extraordinarily long time. Behavioral impairment — impaired judgment, potentially dangerous actions — extends through a full day and night cycle. Sleep deprivation is essentially guaranteed. Post-experience fatigue and psychological vulnerability persist into the following day.
Vasoconstriction and Peripheral Ischemia
DOb and related DOx compounds are associated with significant vasoconstriction. At high doses, severe peripheral vasoconstriction can cause tissue hypoperfusion, similar to ergotamine toxicity, with reported cases of peripheral ischemia. This is a rare but serious physical toxicity not commonly seen with indole psychedelics.
Cardiovascular Strain
Amphetamine-type cardiovascular stimulation (tachycardia, hypertension, vasoconstriction) sustained for 16–30 hours represents substantial risk for individuals with cardiovascular vulnerabilities. Even in healthy individuals, the duration represents an unusual cardiac burden.
Acute Poisoning Events
The greatest documented harm from DOB arises from dose confusion with LSD. Blotter papers sold as LSD containing DOB have produced poisoning events — users who ingest multiple "blotters" assuming LSD potency receive multiple times the active DOB dose, producing overwhelming 24–30+ hour experiences with severe physiological toxicity, including vasoconstriction requiring medical intervention.
Drug Interactions
- MAOIs — potentiated toxicity; absolute contraindication
- Stimulants — compounded cardiovascular strain over the multi-hour duration
- Cannabis — may dramatically intensify and prolong already extreme experience
Addiction Potential
not habit-forming
Overdose Information
Overdose
Internationally, DOB is a Schedule I drug under the Convention on Psychotropic Substances.
Australia: DOB is listed as a Schedule II substance in Australia.
Austria: DOB is illegal to possess, produce and sell under the SMG (Suchtmittelgesetz Österreich).
Canada: DOB is listed as a Schedule 1 as it is an analogue of amphetamine.
Germany: DOB is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of September 1, 1984. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Latvia: DOB is a Schedule I controlled substance.
The Netherlands: DOB is a Lijst 1 substance, making it a harddrug.
New Zealand: DOB is Schedule I (Class A) in New Zealand. DOB would also qualify as an analogue under New Zealand's catch-all analogues section in Schedule 3 / Class C of their drug laws which would make 2C-I, 2C-E, DOI, DOB, ephedrine and pseudoephedrine Schedule 3 compounds in the country.
Poland: DOB is controlled in Poland.
Romania: DOB is a controlled substance, classified as a high-risk drug.
Switzerland: DOB is a controlled substance specifically named under Verzeichnis D.
United Kingdom: DOB is Schedule I/Class A in the U.K., making it illegal to sell, buy, or possess without a license.
United States: DOB is Schedule I in the U.S., making it illegal to sell, buy, gift, produce or possess without a DEA license.
Responsible use
Research chemical
Substituted amphetamine
Phenethylamine
DOB (Wikipedia)
DOB (Erowid Vault)
DOB (PiHKAL / Isomer Design)
Discussion
The Big & Dandy DOB Thread (Bluelight)
Tolerance
| Full | almost immediately after ingestion |
| Half | 4-7 days |
| Zero | 7-10 days |
Cross-tolerances
Legal Status
Internationally, DOB is a Schedule I drug under the Convention on Psychotropic Substances.
Australia: DOB is listed as a Schedule II substance in Australia.
Austria: DOB is illegal to possess, produce and sell under the SMG (Suchtmittelgesetz Österreich).
Canada: DOB is listed as a Schedule 1 as it is an analogue of amphetamine.
Germany: DOB is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of September 1, 1984. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Latvia: DOB is a Schedule I controlled substance.
The Netherlands: DOB is a Lijst 1 substance, making it a harddrug.
New Zealand: DOB is Schedule I (Class A) in New Zealand. DOB would also qualify as an analogue under New Zealand's catch-all analogues section in Schedule 3 / Class C of their drug laws which would make 2C-I, 2C-E, DOI, DOB, ephedrine and pseudoephedrine Schedule 3 compounds in the country.
Poland: DOB is controlled in Poland.
Romania: DOB is a controlled substance, classified as a high-risk drug.
Switzerland: DOB is a controlled substance specifically named under Verzeichnis D.
United Kingdom: DOB is Schedule I/Class A in the U.K., making it illegal to sell, buy, or possess without a license.
United States: DOB is Schedule I in the U.S., making it illegal to sell, buy, gift, produce or possess without a DEA license.
Responsible use
Research chemical
Substituted amphetamine
Phenethylamine
DOB (Wikipedia)
DOB (Erowid Vault)
DOB (PiHKAL / Isomer Design)
Discussion
The Big & Dandy DOB Thread (Bluelight)
Experience Reports (1)
Tips (7)
Avoid binge patterns with DOB. Sleep deprivation combined with stimulant use dramatically increases psychosis risk after 48+ hours awake. If you find yourself redosing to avoid the comedown, that is a major warning sign.
Do not take DOB in the afternoon or evening if you want to sleep that night. Most stimulants have long half-lives and even if you feel you can sleep, the quality will be significantly impaired.
Supplement magnesium glycinate when using DOB to reduce jaw clenching, muscle tension, and bruxism. Also maintain electrolytes, B vitamins, and vitamin C which are depleted faster under stimulant use.
Weigh your dose of DOB with a milligram scale. Street stimulants vary wildly in purity and potency. What looks like a normal amount could be significantly stronger than expected, especially with a new batch.
DOB is active in the low milligram range (1-3mg). Even small errors in measurement can mean the difference between a moderate trip and a medical emergency. An accurate milligram scale (0.001g) is absolutely essential — do not eyeball this substance.
DOB and other DOx compounds are potent vasoconstrictors at higher doses. There are documented cases of peripheral ischemia requiring medical attention. If you experience persistent numbness, discoloration, or severe cold in your extremities during a trip, seek medical help immediately.
Community Discussions (1)
See Also
Same Class
References (5)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- PubChem: DOB
PubChem compound page for DOB (CID: 62065)
pubchem - DOB - TripSit Factsheet
TripSit factsheet for DOB
tripsit - DOB - Wikipedia
Wikipedia article on DOB
wikipedia